Neutron slips to 2027; Rocket Lab falls 14%, about half before news

Rocket Lab launches small satellites on its Electron rocket and builds spacecraft and parts. It launched 12 Electron rockets in the first half of 2026 and had 18 launches in the year by late September.¹ Most revenue now comes from building hardware: space systems brought in $189.5 million of the $234.1 million second-quarter total, against $44.6 million from launches.² One government customer made up 42% of six-month revenue, and its launch rivals include Northrop Grumman, SpaceX and United Launch Alliance.³

Neutron is the company's upcoming reusable medium-lift rocket, designed to carry about 13,000 kg to low Earth orbit when its booster is reused. News coverage calls it the vehicle meant to challenge SpaceX's dominant Falcon 9.¹ Customers are already signed: Kepler Communications booked a Neutron launch from Virginia for no earlier than 2028, and a Space Force contract worth up to $397 million, counting options, covers Rocket Lab spacecraft that will launch on Neutron.² Chief executive Peter Beck has also said Neutron capacity must be kept for Rocket Lab's own use once it owns Iridium, though Iridium's current satellites are good into 2035.³

The first flight has moved before. In late 2025, news reports said Rocket Lab had delayed it into the next year, with the rocket due at its launch site during the first three months of 2026.¹ Then a first-stage tank failed a qualification test in January 2026, and the annual report targeted a first launch in the fourth quarter of 2026.² In May the company said it was in position to fly that year. With second-quarter results in August, the goal became getting the rocket to the pad in the fourth quarter rather than launching it then, and the shares fell 7% in extended trading.³ Beck said the team was balancing launch timing against how quickly it could scale production.⁴ On August 11 he also said the company was pushing hard and intended to launch Neutron for the first time this year, while telling investors not to focus on just the first flight.⁵

The delay lands in the middle of a much bigger deal. On June 28, 2026, Rocket Lab agreed to buy Iridium Communications, which runs 66 satellites and which Beck says brought in more than $870 million of revenue over the past year.¹ Each Iridium share gets $27.00 in cash plus Rocket Lab stock, and at a Rocket Lab price of $67.50 or less the stock part is fixed at 0.4000 shares. Rocket Lab says the deal needs over $3.0 billion in cash, and closing does not depend on it finding financing.²

To pay for it, Rocket Lab sold 29.3 million new shares and, as of September 15, 2026, had raised about $1.944 billion before fees. It then ended a $3.6 billion bridge loan commitment.¹ Iridium's $1.775 billion of term loans will stay in place, and Rocket Lab's main operating company will give an unsecured guarantee of them once the deal closes. Closing is expected in mid-2027, pending regulatory approvals.²

The stock was already far below its spring level. One officer's sale notice shows 36,860 shares sold in late May 2026 for about $147.42 each, and the stock was $80.04 on August 10.¹ It closed at $63.54 on September 15, rallied to $75.05 on October 6, and closed at $64.22 on October 13.² On October 1, chief financial officer Adam Spice exercised options and sold 140,157 shares at about $70.28 to $71.79. The sale notice names a trading plan adopted on June 3, 2026, the date the 10-Q gives for his pre-set selling plan under SEC rules.³

The filing itself is brief. In its main section, Rocket Lab says Neutron's first launch is now expected to shift into next year as the team keeps developing the rocket and adds process improvements.¹ It says it is progressing through key manufacturing and testing milestones and will give more updates as work continues.² It names no milestone, no quarter and no cost, and the details sit in a slide presentation on its investor website, which is not part of the filing.³

Because the filing puts no dollar figure on the delay, the way to size it is against the company. After its share sales, Rocket Lab had about 628 million common shares plus 40,951,250 preferred shares that convert one for one, about 669 million in all, so the $64.22 close on October 13 valued it near $42.9 billion.¹ The company counts those preferred shares in its own basic share count, about 41 million of a guided 641 million for the third quarter. That is about 49 times its first-half revenue of $434.4 million on a yearly basis, a price that leans heavily on growth still to come.² At $54.95 after hours the shares are worth about $36.7 billion. That is about $2.8 billion below the $39.6 billion they were worth at $59.195 just before the 16:40 ET release, and $6.2 billion below the October 13 close.³

The cost of waiting shows up in cash. In the first half of 2026, operations used $134.4 million and equipment purchases took another $53.1 million, a combined $187.5 million.¹ The 10-Q warns that more Neutron delays may require more research, development and capital spending than the company now expects.²

Reported results and the company's preferred measure tell different stories. In the second quarter Rocket Lab lost $57.5 million from operations under standard accounting, but only $8.8 million on adjusted EBITDA, which is earnings before interest, taxes, depreciation and amortization.¹ The company says that measure also leaves out items it calls unrepresentative of its ongoing operations.² Most of the $48.7 million gap is stock pay of $19.6 million, deal costs of $8.6 million and about $19.4 million of depreciation and amortization. The net loss was smaller, at $49.3 million, because the cash pile earned $16.5 million of interest.³

The company's own third-quarter goals, set in August before this delay, already pointed to thinner margins. It guided revenue of $250 million to $265 million and a standard gross margin of 29% to 31%, down from 36.1% in the second quarter.¹ It also guided an adjusted EBITDA loss of $17 million to $23 million, against $8.8 million in the second quarter.²

Rocket Lab can afford a longer wait, but much of its cash already has a job. It held $2.39 billion of cash and marketable securities at June 30, and by September 15 it had raised $1.944 billion of gross share proceeds, about $4.3 billion before what it has spent since.¹ The Iridium deal needs over $3.0 billion in cash at closing, and Rocket Lab must pay it even without new financing.² Management says its cash covers working capital and equipment needs for at least the next twelve months, and that share proceeds, Iridium's loans and other cash will cover the payments due at closing.³

Debt is light today: only $13.4 million of convertible notes were left at June 30. Because adjusted EBITDA is negative, a ratio of net debt to EBITDA means little here, and the company holds far more cash than debt.¹ That changes at closing, when Rocket Lab's main operating company guarantees Iridium's $1.775 billion of term loans, priced at SOFR, a benchmark lending rate, plus 2.50% to 3.00%.²

Shareholders have paid for this flexibility in new stock. The 29.3 million shares sold added about 4.9% to the 598.4 million outstanding on August 5, at an average of about $66 a share.¹ The preferred shares belong to a family trust set up by Beck. Add 13,095,520 options and stock units, 2,607,745 note shares and 7,451,200 shares under forward sale contracts to the roughly 669 million, and the count is about 692 million.² The Iridium deal can add up to 45,989,148 more, for about 738 million.³ Lenders come ahead of shareholders. In a wind-down the preferred gets a token $0.0001 a share first and then shares what is left with common stock as if converted.⁴ A funding agreement with the Department of Commerce bars dividends and buybacks without approval.⁵

The price drop also changes the Iridium arithmetic. At or below $67.50, Rocket Lab hands over the maximum 0.4000 shares per Iridium share, so Iridium holders get less in dollars while Rocket Lab's share issuance is capped: a further fall in its price adds no new deal shares.¹ The deal's own table shows $51.00 per Iridium share at a $60.00 Rocket Lab price. At $54.95, the $27.00 in cash plus 0.4000 shares comes to about $48.98, against the $54 headline price.² Iridium traded at $45.80 at 3:59 PM, about 9.6% below the $50.68 its holders would have received at Rocket Lab's price that minute (an 11% gain if the deal closed at that price), a gap that prices both the wait to an expected mid-2027 closing and the risk the deal does not close.³

RKLB moved down 14.4% from its October 13 close of $64.22 to $54.95 at 16:45 ET on October 14. SPY, the S&P 500 fund, moved down 1.2% over the same span, from $778.03 to $768.84.¹ Much of the fall came before the news: RKLB traded at $59.195 at 3:59 PM, a 7.8% drop in regular trading, and the release went out at 16:40 ET.²

The strongest bull case is that Neutron is late but the company around it is not. Backlog was a record $2.36 billion at June 30, with about 45% expected to become revenue within 12 months.¹ In late September a 20-launch Synspective deal pushed the launch backlog beyond 100 missions, and Rocket Lab had launched 18 times in 2026 by then.² Second-quarter revenue grew 62%. Iridium, in management's words, generates pretty significant free cash flow and is not a big hole in the profit and loss statement.³

The bear case, strongest point first. The first flight has now slipped twice this year: the January tank failure moved it to the fourth quarter of 2026, and it is now 2027 with no quarter named.¹ Second, the company itself warns that delays may need more research and capital spending, on top of the $187.5 million used in the first half. Third, Neutron work is already sold: the Space Force contract of up to $397 million, a figure that counts options, covers spacecraft that launch on Neutron, and backlog contracts typically carry termination rights.² Fourth, near-term results are heading the wrong way, with a bigger adjusted EBITDA loss guided for the third quarter. And the Iridium deal brings what Beck calls a relatively slow-growing business, plus new shares and a guaranteed $1.775 billion loan.³

The company's own forward case is made of goals, not results: a first Neutron flight in 2027, an Iridium closing in mid-2027, a first suborbital launch of its GHOST portable launch system from Alaska in 2027, and Kepler's Neutron mission no earlier than 2028.¹ Synspective's 20 new Electron launches are scheduled each year from 2028 through 2031.²

What would prove the bears wrong is a dated plan: a named quarter for the first launch, spending guidance that does not jump, and the rocket's arrival at its pad, which in August was targeted for the fourth quarter of 2026.¹ The first chance is the third-quarter report, whose date Rocket Lab has not announced. The Iridium deal's end date is June 28, 2027, and it can roll to December 28, 2027 if only regulatory approvals remain.² Spice's selling plan runs to August 31, 2027, and the forward sale contracts are scheduled to mature in April 2028. If RKLB cannot get back above the $67.50 collar floor by year end, the market will be treating this as more than a timing slip.³

No filing names a quarter or month in 2027 for the first launch. Rocket Lab points readers to a presentation on its investor website for further details.

No filing puts a figure on the extra research, equipment or launch-site spending the delay may need, or says whether the August outlook for the third quarter still holds.

No filing says how much of the $940.2 million launch backlog at June 30, or of the $2.36 billion total, depends on Neutron rather than Electron.

The filings do not say whether Neutron customers, such as the Space Force program or Kepler, can cancel, reprice or claim damages if the first flight comes later. The 10-Q says only that launch and spacecraft contracts typically include termination rights.

Iridium's stockholders were due to vote on September 24, 2026, and no Rocket Lab filing since then reports the result.

Rocket Lab has not announced when it will report third-quarter results.